In human head and neck carcinoma cells, ESRP1 and ESRP2 decrease cell motility,13 and ESRP2 inhibits the proliferation of clear-cell renal cell carcinoma cells.12 In agreement with these in vitro findings, ESRP1 suppresses tumorigenic potential in colorectal cancer14 and attenuates liver metastases in pancreatic cancer in vivo. Here, ESRP2 is linked to pancreatic neoplasm.